MYELOMA
Clinical trials for MYELOMA explained in plain language.
Never miss a new study
Get alerted when new MYELOMA trials appear
Sign up with your email to follow new studies for MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Shot-Based myeloma combo aims to simplify treatment for older patients
Disease control OngoingThis study tests a new way to give the drug isatuximab—as a quick shot under the skin instead of a long IV drip—for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. About 74 participants aged 65 and older will receive the shot along wi…
Matched conditions: MYELOMA
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New drug timing may keep myeloma in check longer
Disease control OngoingThis study tests a different way of giving chemotherapy to people with multiple myeloma who have already received some treatment but not a transplant. The goal is to give lower doses of drugs in shorter cycles so that cancer cells have less time to grow back between treatments. R…
Matched conditions: MYELOMA
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New drug combo shows promise in keeping myeloma in check after transplant
Disease control OngoingThis study tests whether adding the drug belantamab mafodotin before and after a stem cell transplant can help control multiple myeloma better than standard care. About 41 adults with myeloma who have had limited prior treatment will receive the drug alongside standard chemothera…
Matched conditions: MYELOMA
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
Powerful 4-Drug cocktail aims to crush myeloma early
Disease control OngoingThis study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in 75 people newly diagnosed with multiple myeloma. The goal is to see how many achieve a very deep remission (stringent complete response) and have no detectable cancer cells…
Matched conditions: MYELOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take on tough blood cancers
Disease control OngoingThis study tests a new treatment for people with certain blood cancers (lymphoma, multiple myeloma, or CLL) that have returned or not responded to standard therapy. Researchers take a patient's own immune cells (T cells) and modify them in the lab to better recognize and attack c…
Matched conditions: MYELOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for elderly myeloma patients: drug combo aims to deepen remission without transplant
Disease control OngoingThis phase 3 study tests whether adding the drug isatuximab to a standard two-drug regimen (lenalidomide and dexamethasone) works better with or without a third drug (bortezomib) for older adults (65-79) newly diagnosed with multiple myeloma who are not eligible for a stem cell t…
Matched conditions: MYELOMA
Phase: PHASE3 • Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New imaging agent could light up tumors for better cancer detection
Knowledge-focused OngoingThis early-phase study uses a tiny amount of a radioactive drug called 124I-PUH71 to take PET scans of cancer patients. The goal is to see where the drug goes in the body, including into tumors, and how long it stays in the blood. About 63 people with lymphoma, myeloma, or other …
Matched conditions: MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 04:14 UTC